Glenmark Pharmaceuticals Inc., USA is voluntarily recalling approximately 4,048,740 bottles of Ranitidine Tablets (both 150 mg and 300 mg strengths) after tests detected a nitrosamine impurity called N-Nitrosodimethylamine (NDMA) in the product. Ranitidine is a prescription medication used to treat stomach ulcers, gastroesophageal reflux disease (GERD), and conditions where the stomach makes too much acid. These products were manufactured in India and distributed nationwide across the United States. Consumers should consult their healthcare provider for alternative treatment options and instructions on how to safely return the affected medication.
NDMA is classified as a probable human carcinogen, meaning it is a substance that could cause cancer. This recall was initiated because the tablets contain levels of NDMA that exceed the limits established by the FDA.
Pharmaceutical guidance and partial/full refund through pharmacy return.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.